The stages of autoimmune Type 1 diabetes (T1D)
Find out how your T1D is staged
The stages of T1D1–4
Although you may not have experienced any symptoms yet, you have been identified as having Stage 2 T1D because you have at least 2 autoantibodies in your blood and abnormal blood sugar levels.
You will experience symptoms when you reach Stage 3 T1D. Tzield may help to keep you in Stage 2 for longer and delay the start of Stage 3 T1D.
Adapted from Insel RA, et al. Diabetes Care. 2015; 38(10): 1964–1974.2
What are autoantibodies?2,3
When your immune system attacks your beta cells, it releases proteins called autoantibodies into your blood. These autoantibodies can be detected in the blood and measured to help assess whether you have T1D and establish the stage of your disease.
Tzield is a medicine used to delay the start of Stage 3 Type 1 diabetes. This condition happens when the body cannot make enough insulin on its own and may need insulin injections. This medicine is used in adults and children aged 8 years and older who have Stage 2 Type 1 diabetes.5
If you have any questions on how Tzield works or about your treatment with Tzield, ask your doctor.
This website is not intended to be a substitute for medical advice. Please refer to the Patient information leaflet and the Patient Guide for full safety information. You may have received these items from your doctor already.
The contents of this website have been developed and funded by Sanofi.
References:
- TZIELD® (teplizumab) UK Summary of Product Characteristics. Accessed: November 2025.
- Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015; 38(10): 1964–1974.
- Sims EK, Besser REJ, Dayan C, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022; 71(4): 610–623.
- Phillip M, Achenbach P, Addala A, et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care. 2024; 47(8): 1276–1298.
- TZIELD® (teplizumab) UK Patient Information Leaflet. Accessed: November 2025.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store.
Alternatively, you can report side effects to Sanofi on Tel: 0800 0902 314 or send via email to UK-drugsafety@sanofi.com. By reporting side effects, you can help provide more information on the safety of this medicine.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.
© 2025 Sanofi. All rights reserved. MAT-XU-2501107 (V1.0) | November 2025
Welcome to Tzield
Welcome to Tzield
This website and its contents have been developed by Sanofi for patients in the United Kingdom who have been prescribed Tzield.
In order to proceed into the website, please confirm that you are, or you care for, a patient in the United Kingdom prescribed Tzield by clicking the confirmation button below.
MAT-XU-2503330 (V1.0) - Date of preparation: November 2025